D Lorente
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer
Pezaro C, Sohaib A, de Bono J, Dearnaley D, Parker C, Lorente D, Bianchini D, Attard G, Mukherji D, Perez-Lopez R, Omlin A, Tunariu N. Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer. Clin Radiol 2014
30.12.2014Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer
30.12.2014Clin Radiol 2014
Pezaro C, Sohaib A, de Bono J S, Dearnaley D, Parker C, Lorente D, Bianchini D, Attard G, Mukherji D, Perez-Lopez R, Omlin Aurelius, Tunariu N
Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
Lorente D, Sartor O, Su Z, Shen L, Bahl A, Ferraldeschi R, Bianchini D, Zafeiriou Z, Templeton A, Mateo J, de Bono J. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol 2014
23.12.2014Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use
23.12.2014Ann Oncol 2014
Lorente D, Sartor O, Su Z, Shen L, Bahl A, Ferraldeschi R, Bianchini D, Zafeiriou Z, Templeton Arnoud, Mateo J, de Bono J S
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
Lorente D, de Bono J, Gillessen Sommer S, Dearnaley D, Parker C, Tunariu N, Zafeirou Z, Altavilla A, Mateo J, Perez R, Pezaro C, Ferraldeschi R, Omlin A, Attard G. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer 2014
14.10.2014Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
14.10.2014Br J Cancer 2014
Lorente D, de Bono J, Gillessen Sommer Silke, Dearnaley D, Parker C, Tunariu N, Zafeirou Z, Altavilla A, Mateo J, Perez R, Pezaro C, Ferraldeschi R, Omlin Aurelius, Attard G
Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
Omlin A, de Bono J, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C, Attard G. Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'. Br J Cancer 2013; 110:267-8.
03.12.2013Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
03.12.2013Br J Cancer 2013; 110:267-8
Omlin Aurelius, de Bono J S, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C J, Attard G
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
Bianchini D, de Bono J, Scher H, Attard G, Rathkopf D, Buchbinder A, Zivi A, Riisnaes R, Miranda S, Figueiredo I, Crespo M, Mukherji D, Ferraldeschi R, Lorente D, Pezaro C, Omlin A, Danila D. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer 2013; 109:2579-86.
29.10.2013First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
29.10.2013Br J Cancer 2013; 109:2579-86
Bianchini D, de Bono J, Scher H I, Attard G, Rathkopf D E, Buchbinder A, Zivi A, Riisnaes R, Miranda S, Figueiredo I, Crespo M, Mukherji D, Ferraldeschi R, Lorente D, Pezaro C, Omlin Aurelius, Danila D C
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
Bianchini D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin A, Rodriguez-Vida A, Lorente D, de Bono J. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 2013; 50:78-84.
25.09.2013Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
25.09.2013Eur J Cancer 2013; 50:78-84
Bianchini D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin Aurelius, Rodriguez-Vida A, Lorente D, de Bono J S
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
Omlin A, de Bono J, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C, Attard G. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. Br J Cancer 2013; 109:1079-84.
08.08.2013Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
08.08.2013Br J Cancer 2013; 109:1079-84
Omlin Aurelius, de Bono J S, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C J, Attard G